Sophia Constance Kamran

Sophia Constance Kamran

Auto-generated profile, based on publicly available information

Sophia Constance Kamran

Department of Radiation Oncology, Mass General Brigham , 800 Boylston St., 02199 Boston, MA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2013 in Science
Verified
Journal Article
Closed access
PDF file
DBDaniel E. Bauer
Daniel E. Bauer
SKSophia C. Kamran
Sophia C. Kamran
SLSamuel Lessard
Samuel Lessard
JXJian Xu
Jian Xu
YFYuko Fujiwara
Yuko Fujiwara
SOStuart H. Orkin
Stuart H. Orkin
BCL11A Variants: Recent chromatin mapping data have suggested that trait-associated variants often mark regulatory DNA. However, there has been little rigorous experimental investigation of regulatory variation. Bauer et al. (p. 253 ; see the Perspective by Hardison and Blobel ) performed an in-depth study of the BCL11A fetal hemoglobin-associated locus. The trait-associated variants revealed a chromatin signature that enhanced erythroid development. The enhancer was required for erythroid expression of BCL11A and thus for globin gene expression.

1 February 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SKSophia C. Kamran
Sophia C. Kamran
EMEllen Marqusee
Ellen Marqusee
MKMathew I. Kim
Mathew I. Kim
MFMary C. Frates
Mary C. Frates
JRJulie Ritner
Julie Ritner
EAErik K. Alexander
Erik K. Alexander
Thyroid nodule size is routinely measured, although its impact on thyroid cancer risk is unclear. Our objective was to evaluate the association of nodule size upon cancer risk. We conducted a retrospective cohort analysis at an academic hospital with 4955 consecutive patients evaluated between 1995 and 2009. Ultrasound and ultrasound-guided fine-needle aspiration of nodules >1 cm was done. Indeterminate and malignant nodules were referred for surgery, and histopathology was reviewed. The presence and histological subtype of cancer was evaluated. Of 7348 evaluated nodules, 927 (13%) were cancerous. Of those 1.0 to 1.9 cm in diameter, 10.5% were cancerous. In contrast, of those >2.0 cm, 15% were cancerous (P < .01). However, nodules 2.0 to 2.9, 3.0 to 3.9, and >4 cm were cancerous in 14%, 16%, and 15% of cases (P = .14), respectively, demonstrating no graded increase in risk beyond the 2-cm threshold. When malignant, the proportion of papillary carcinoma decreased (nodules 1.0-1.9 cm, 92% of cases; 2.0-2.9 cm, 88%; 3.0-3.9 cm, 83%; >4 cm, 74% [P < .01]), while follicular carcinoma increased (1.0-1.9 cm, 6%; 2.0-2.9 cm, 7%; 3.0-3.9 cm, 12%; >4 cm, 16% [P < .01]) as nodules enlarged. Nodules size did not influence cytology distribution or risk of false-negative aspirates. Increasing thyroid nodule size impacts cancer risk in a nonlinear fashion. A threshold is detected at 2.0 cm, beyond which cancer risk is unchanged. However, the risk of follicular carcinomas and other rare thyroid malignancies increases as nodules enlarge.

8 November 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
CAChristopher M. Aldrighetti
Christopher M. Aldrighetti
ANAndrzej Niemierko
Andrzej Niemierko
EAEliezer Van Allen
Eliezer Van Allen
HWHenning Willers
Henning Willers
SKSophia C. Kamran
Sophia C. Kamran
Precision medicine has revolutionized oncology in the past 2 decades and is expected to continue to transform cancer management. The principle of personalized cancer therapy incorporates a multi-omic (eg, genomic, transcriptomic, metabolomic, proteomic, epigenetic) approach along with other tumor- and patient-specific factors. The identification of biomarkers facilitates stratifying patients and guiding treatment individualization, leading to improved outcomes.1 Much biomarker discovery and translational research that contribute to personalized treatments come from well-designed studies that incorporate precision medicine principles. Additionally, knowledge learned from studies that are designed to collect translational data can be used as part of discovery for predictive and prognostic biomarkers, which then can be applied to personalized therapeutic regimens.

11 October 2012 in Blood
Verified
Journal Article
Open access
PDF file
DBDaniel E. Bauer
Daniel E. Bauer
SKSophia C. Kamran
Sophia C. Kamran
SOStuart H. Orkin
Stuart H. Orkin
The level of fetal hemoglobin (HbF) modifies the severity of the common β-globin disorders. Knowledge of the normal mechanisms that repress HbF in the adult stage has remained limited until recently despite nearly 3 decades of molecular investigation, in part because of imperfect model systems. Recent studies have provided new insights into the developmental regulation of globin genes and identified specific transcription factors and epigenetic regulators responsible for physiologic silencing of HbF. Most prominent among these regulators is BCL11A, a transcriptional repressor that inhibits adult-stage HbF expression. KLF1 and c-Myb are additional critical HbF-regulating erythroid transcription factors more broadly involved in erythroid gene expression programs. Chromatin modifiers, including histone deacetylases and DNA methyltransferases, also play key roles in orchestrating appropriate globin gene expression. Taken together, these discoveries present novel therapeutic targets for further consideration. Although substantial hurdles remain, opportunities are now rich for the rational design of HbF inducers.

1 July 2015 in Surgical Oncology Clinics of North America
Verified
Journal Article
Closed access
SKSophia C. Kamran
Sophia C. Kamran
NRNadeem Riaz
Nadeem Riaz
Nancy LeeNancy Lee
Nancy Lee

1 September 2015 in Molecular Therapy
Verified
Journal Article
Open access
SGSwaroopa Guda
Swaroopa Guda
CBChristian Brendel
Christian Brendel
RRRaffaele Renella
Raffaele Renella
PDPeng Du
Peng Du
DBDaniel E Bauer
Daniel E Bauer
DWDavid A Williams
David A Williams
RNA interference (RNAi) technology using short hairpin RNAs (shRNAs) expressed via RNA polymerase (pol) III promoters has been widely exploited to modulate gene expression in a variety of mammalian cell types. For certain applications, such as lineage-specific knockdown, embedding targeting sequences into pol II-driven microRNA architecture is required. Here, using the potential therapeutic target BCL11A, we demonstrate that pol III-driven shRNAs lead to significantly increased knockdown but also increased cytotoxcity in comparison to pol II-driven microRNA adapted shRNAs (shRNAmiR) in multiple hematopoietic cell lines. We show that the two expression systems yield mature guide strand sequences that differ by a 4bp shift. This results in alternate seed sequences and consequently influences the efficacy of target gene knockdown. Incorporating a corresponding 4bp shift into the guide strand of shRNAmiRs resulted in improved knockdown efficiency of BCL11A. This was associated with a significant de-repression of the hemoglobin target of BCL11A, human γ-globin or the murine homolog Hbb-y. Our results suggest the requirement for optimization of shRNA sequences upon incorporation into a microRNA backbone. These findings have important implications in future design of shRNAmiRs for RNAi based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences.